Center Overview

Hawaii Pacific Neuroscience Clinical Research Center (CRC) proven model, and combined years of experience affords us the ability to provide Hawaii patients with groundbreaking new neuroscience treatment options.
Our staff includes 8 fulltime Investigators, 5 dedicated full-time research staff and over 10 administrative support staff with Regulatory, Quality Assurance, Business Development, Recruitment Specialists. CRC has an active database of over 20,000 subjects and growing. Principal Investigator Kore Liow, MD, an NIH trained research neurologist has served as PI for over 20 years for more than 100 phase I through IV neuroscience clinical trials funded by NIH, CDC, and the industry and published over 40 peer-reviewed scientific neuroscience articles.

Focus on Reducing Health Disparities in US Minority Populations
 
According to NIH NIMHD (National Institute on Minority Health & Health Disparities), one of America’s greatest challenges is reducing the profound disparity in health status of its racial and ethnic minority, rural, low-income, and other underserved populations.  Hawaii is one of the most diverse state and home to several NIMHD designated US health disparity populations including:

  • Asian Americans (40% of Hawaii’s Population)
  • Native Hawaiians and other Pacific Islanders
  • Socioeconomically disadvantaged populations
  • Underserved Rural populations (94% of Total Land area housing 8% of population in Hawaii)

Clinical Research Center at Hawaii Pacific Neuroscience goal is to contribute to NIH NIMHD’s goals of “enhancing the scientific knowledge base and designing interventions to improve health outcomes to reduce and ultimately lead to the elimination of health disparities’ by ensuring that clinical trials include racial and ethnic diversity including minority groups that constitute substantial and growing proportions of the US population.  For example,according to the 2010 US census , 6% of those identified themselves as Asian.  It is important for clinical trial populations to reflect the targeted patient population.  Our trial subjects at Clinical Research Center strive to represent the trial populations that are an important facet of clinical trial designs and positively contribute to the scientifically rigorous evaluation of therapies being investigated to ensure that the safety and efficacy profile of a treatment is accurate.
 
Hawaii Pacific Neuroscience is committed to improving health care access, reducing health disparities especially for minorities and those underserved in our state and proud to be working with organizations to serve these populations.  Further information, contact Principal Investigator Kore Kai Liow, MD, kliow@HawaiiNeuroscience.com

Staff Expertise

Principal Investigator

Dr. Kore Kai Liow is a board-certified neurologist with over 20 years of clinical research experience. He has personally served as the PI for over 100 Phase I-IV neuroscience clinical trials. His research has been published in over 40 peer-reviewed publications and has received the “Honolulu Top Doctors” award in 2015, 2016 and 2017.


READ MORE


Sub-Investigators


Basic Science Research and Collaborations

Regulatory & Start Up Department

Our CRC Regulatory Specialists process the start-up paperwork with a turn-around time of less than one week and work diligently to maintain all regulatory documents throughout the study.

Clinical Research Department

Our CRC Coordinators and Assistants are the backbone of the department. They work directly under the PI and manage the day-to-day logistics of the clinical trials. The team leaders have extensive research experience and provide oversight with the PI to ensure the proper management of multiple trials.

Pharmacy Department

Our CRC licensed pharmacy technician provides oversight and direction of the pharmacy department to keep track of all IP involved including receiving, inventory, tracking, dispense, drug distribution and providing technical assistance with clinical protocol including coordinating, collaborating and providing expertise in support of the clinical trials as well improving patient experience in education of AEs.

Recruitment & Business Development

Our CRC Recruitment and Business Development Team work closely with the PI and Study Coordinators to pursue all avenues of patient recruitment, which leads to our study site frequently exceeding the enrollment standards set by our study sponsors.

Performance Metrics

  • Number of Studies Completed: over 100
  • Number of Active Patients in the Database: over 20,000
  • Regulatory Submission Turn-Around Time: 7 Business Day(s)
  • Average Percent of Total Patients Randomized: 90 %
  • Average Percent of ‘Completed’ Studies that met Enrollment Goals: 95 %
  • EDC Capabilities: Yes

Therapeutic Areas

Phase One to Four and IV Capable

Alzheimer’s Research Unit

Epilepsy Research Unit

Parkinson’s Research Unit

Vaccine Research Unit

MS & Neuroimmunology Research Unit

Stroke Research Unit

Sleep & insomnia Research Unit

Pain Research Unit

Headache & Migraine Research Unit

ALS Research Unit

Neuromodulation Research Unit

Brain Health & Wellness

Recent Products Investigated at Clinical Research Center,
Approved by FDA and Launched in US.

  • Inbrija for Parkinson’s (Successfully Tested at CRC 2016-2018)
  • XCorpi for Epilepsy ( Successfully Tested at CRC 2016-2019)
  • Kesimpta for MS ( Successfully Tested at CRC 2018-2021)
  • Valtoco for Epilepsy ( Successfully Tested at CRC 2017-2019)

Recent Achievements (2017-2018)

  • #1 Recruitment site for Western US in ALZHEIMER’S DAYBREAK Eli Lily study
  • #1 Recruitment site in US for EPILEPSY Aquestive Monosol PK study
  • #1 Recruitment site in US for PARKINSON’S Tozadenant Biotie study
  • FIRST in US to fulfill enrollment quota in OMB MS (MULTIPLE SCLEROSIS) Novartis study
  • FIRST in US to screen and enroll patients in EPILEPSY Padsevonil ARISE UCB study
  • FIRST in US to screen and enroll patients in EPILEPSY Natalizumab Biogen Study

Facility Description

  • 20 exam rooms
  • 2 dedicated research/monitor rooms
  • 24 hour/day staffed phase I overnight unit
  • AASM (American Academy of Sleep Medicine) Accredited 4-bed overnight Sleep Laboratory
  • 4 Bed Video-EEG Epilepsy Monitoring Unit (EMU)
  • Licensed and experienced staff for IV Infusion and PK studies
  • Experienced and approved raters for Neurologic and Cognitive ratings
  • On-site EEG and Video-EEG
  • On-site EMG
  • On-site ECG machine(s)
  • On-site Radiology Dept. / MRI Machine
  • On-site Neuroradiology expertise including Fluoroscopic Spinal Tap/LP capabilities
  • On-site Neuroradiology expertise including Fluoroscopic Spinal Tap/LP capabilities
  • Accredited Local Laboratory
  • Blood Pressure devices
  • Refrigerator
  • -20C freezer
  • Ambient temperature centrifuge
  • Refrigerated centrifuge
  • High-Speed Internet included in the monitor rooms
  • Study-dedicated fax machine
  • Locked/secure Drug storage that is temperature controlled and monitored daily
  • Equipped with emergency resuscitation equipment
  • Staff is IATA certified
  • Experience with the use of Central laboratories
  • Facility for long-term storage of files for completed studies
  • Ongoing GCP training

Interested in Research?